A Two-Part Phase 1 Healthy Volunteer Study: A Crossover Comparison of CTP-656 Solid Dose Formulation vs. Kalydeco and a Double-Blind, Placebo-Controlled, Ascending Multiple Dose Evaluation of CTP-656

Trial Profile

A Two-Part Phase 1 Healthy Volunteer Study: A Crossover Comparison of CTP-656 Solid Dose Formulation vs. Kalydeco and a Double-Blind, Placebo-Controlled, Ascending Multiple Dose Evaluation of CTP-656

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Sep 2016

At a glance

  • Drugs Ivacaftor deuterated (Primary) ; Ivacaftor
  • Indications Cystic fibrosis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Concert Pharmaceuticals
  • Most Recent Events

    • 21 Sep 2016 According to a Concert Pharmaceuticals media release, results from this study will be presented at the 30th Annual North American Cystic Fibrosis Conference.
    • 10 Jun 2016 Results from this trial were presented at the European Cystic Fibrosis Conference, according to a Concert Pharmaceuticals media release.
    • 10 Jun 2016 Results published in a Concert Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top